JPWO2021186185A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021186185A5 JPWO2021186185A5 JP2022556088A JP2022556088A JPWO2021186185A5 JP WO2021186185 A5 JPWO2021186185 A5 JP WO2021186185A5 JP 2022556088 A JP2022556088 A JP 2022556088A JP 2022556088 A JP2022556088 A JP 2022556088A JP WO2021186185 A5 JPWO2021186185 A5 JP WO2021186185A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- imidazol
- sulfonyl
- butyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 2-hydroxyprop-2-yl Chemical group 0.000 claims 47
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 46
- 150000001875 compounds Chemical class 0.000 claims 32
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 claims 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 7
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 5
- 206010019280 Heart failures Diseases 0.000 claims 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 4
- 206010035664 Pneumonia Diseases 0.000 claims 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 235000010290 biphenyl Nutrition 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229960004588 cilostazol Drugs 0.000 claims 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 claims 1
- 229960003009 clopidogrel Drugs 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 229960001145 deflazacort Drugs 0.000 claims 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000543 intermediate Substances 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 229960004194 lidocaine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960001929 meloxicam Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960003073 pirfenidone Drugs 0.000 claims 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical group C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 229960003712 propranolol Drugs 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 229960003841 selexipag Drugs 0.000 claims 1
- QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 claims 1
- 229960003310 sildenafil Drugs 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 229960000488 tizanidine Drugs 0.000 claims 1
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 claims 1
- 229960005461 torasemide Drugs 0.000 claims 1
- 229960005080 warfarin Drugs 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE2050301-7 | 2020-03-19 | ||
| SE2050301 | 2020-03-19 | ||
| SE2050782 | 2020-06-29 | ||
| SE2050782-8 | 2020-06-29 | ||
| PCT/GB2021/050680 WO2021186185A1 (en) | 2020-03-19 | 2021-03-18 | Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518948A JP2023518948A (ja) | 2023-05-09 |
| JPWO2021186185A5 true JPWO2021186185A5 (https=) | 2024-03-28 |
| JP2023518948A5 JP2023518948A5 (https=) | 2024-03-28 |
Family
ID=75339995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556088A Pending JP2023518948A (ja) | 2020-03-19 | 2021-03-18 | アンギオテンシンｉｉに関連する疾患、障害又は状態の治療及び／又は予防に有用な新規化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230159467A1 (https=) |
| EP (1) | EP4121165A1 (https=) |
| JP (1) | JP2023518948A (https=) |
| KR (1) | KR20230004501A (https=) |
| CN (1) | CN115605265B (https=) |
| AU (1) | AU2021238939A1 (https=) |
| BR (1) | BR112022018549A2 (https=) |
| CA (1) | CA3175559A1 (https=) |
| CL (1) | CL2022002540A1 (https=) |
| CO (1) | CO2022014673A2 (https=) |
| IL (1) | IL296247A (https=) |
| MX (1) | MX2022011613A (https=) |
| PH (1) | PH12022552413A1 (https=) |
| WO (1) | WO2021186185A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4313953A1 (en) * | 2021-03-23 | 2024-02-07 | Vicore Pharma AB | Selective angiotensin ii receptor ligands |
| GB202104033D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| GB202113583D0 (en) * | 2021-09-23 | 2021-11-10 | Vicore Pharma Ab | New compounds |
| MX2024000518A (es) | 2021-07-09 | 2024-01-31 | Vicore Pharma Ab | Nuevos compuestos selectivos de angiotensina ii. |
| JP2024178482A (ja) * | 2021-11-15 | 2024-12-25 | 株式会社アークメディスン | 化合物、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
| IE20230600A3 (en) | 2022-12-22 | 2025-09-24 | Vicore Pharma Ab | A method of treating a patient diagnosed with an interstitial lung disease |
| WO2024149712A1 (en) * | 2023-01-09 | 2024-07-18 | Vicore Pharma Ab | Selective angiotensin ii compounds |
| CN119504723A (zh) * | 2023-08-25 | 2025-02-25 | 武汉人福创新药物研发中心有限公司 | 作为at2r激动剂的噻吩磺酰基氨基甲酸酯 |
| WO2025146172A1 (zh) * | 2024-01-03 | 2025-07-10 | 武汉人福创新药物研发中心有限公司 | 一种并环类化合物作为at2r激动剂 |
| WO2025252142A1 (zh) * | 2024-06-07 | 2025-12-11 | 江苏柯菲平医药股份有限公司 | 一种血管紧张素ii型2受体激动剂及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| KR100938817B1 (ko) * | 2001-05-31 | 2010-01-26 | 바이코어 파마 아베 | 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물 |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| WO2004046141A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| AU2006235698B2 (en) * | 2005-04-12 | 2012-03-29 | Vicore Pharma Ab | New tricyclic angiotensin II agonists |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| DE102012004589A1 (de) | 2012-03-09 | 2013-09-12 | Forschungszentrum Jülich GmbH | Agonisten des Angiotensin II AT2-Rezeptors zur Behandlung neurodegenerativer Erkrankungen |
| BR112017012337A2 (pt) | 2014-12-12 | 2018-02-27 | Vicore Pharma Ab | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. |
| WO2016107879A2 (en) | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| CN107405406A (zh) * | 2015-03-02 | 2017-11-28 | 维科尔药物公司 | 用于治疗肺纤维化的血管紧张素ii受体激动剂 |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
-
2021
- 2021-03-18 KR KR1020227036148A patent/KR20230004501A/ko active Pending
- 2021-03-18 CN CN202180033927.3A patent/CN115605265B/zh active Active
- 2021-03-18 JP JP2022556088A patent/JP2023518948A/ja active Pending
- 2021-03-18 CA CA3175559A patent/CA3175559A1/en active Pending
- 2021-03-18 EP EP21715951.6A patent/EP4121165A1/en active Pending
- 2021-03-18 BR BR112022018549A patent/BR112022018549A2/pt unknown
- 2021-03-18 MX MX2022011613A patent/MX2022011613A/es unknown
- 2021-03-18 IL IL296247A patent/IL296247A/en unknown
- 2021-03-18 US US17/912,284 patent/US20230159467A1/en active Pending
- 2021-03-18 PH PH1/2022/552413A patent/PH12022552413A1/en unknown
- 2021-03-18 AU AU2021238939A patent/AU2021238939A1/en not_active Withdrawn
- 2021-03-18 WO PCT/GB2021/050680 patent/WO2021186185A1/en not_active Ceased
-
2022
- 2022-09-16 CL CL2022002540A patent/CL2022002540A1/es unknown
- 2022-10-18 CO CONC2022/0014673A patent/CO2022014673A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4650412B2 (ja) | チアゾール誘導体およびｖａｐ−１阻害剤としてのその使用 | |
| US20080119462A1 (en) | Method for treating vascular hyperpermeable disease | |
| JP4978464B2 (ja) | Ｖａｐ−１阻害剤活性を有するチアゾール誘導体 | |
| US12458642B2 (en) | Metalloenzyme inhibitor compounds | |
| US20090069288A1 (en) | Novel therapeutic compounds | |
| JP2008508188A5 (https=) | ||
| JPWO2021186185A5 (https=) | ||
| JP2017538697A5 (https=) | ||
| JP2019532052A5 (https=) | ||
| CN1142153C (zh) | 苯甲酰哒嗪 | |
| US11136309B2 (en) | Metalloenzyme inhibitor compounds | |
| JP2004532276A5 (https=) | ||
| JP2012501334A5 (https=) | ||
| JPWO2020163337A5 (https=) | ||
| JPWO2021110805A5 (https=) | ||
| JPWO2021186180A5 (https=) | ||
| JPWO2022200785A5 (https=) | ||
| WO2001047895A1 (en) | Novel compounds having five-membered hetero-aromatic rings |